Author Archives: admin


Stem Cell Clinic > Articles by: admin

Latest Research Highlighting VASCEPA®/VAZKEPA® (icosapent ethyl) REDUCE-IT® Subgroup Data and New Mechanistic Insights into Eicosapentaenoic Acid…

By Global News Feed

DUBLIN, Ireland and BRIDGEWATER, N.J., Aug. 22, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced new supported and/or funded subgroup data from the landmark REDUCE-IT® cardiovascular outcomes trial with VASCEPA®/VAZKEPA® (icosapent ethyl), as well as abstracts showcasing the mechanistic activity of eicosapentaenoic acid (EPA) that will be presented at the European Society of Cardiology (ESC) Congress in London, United Kingdom, August 30 – September 2, 2024.

View original post here:
Latest Research Highlighting VASCEPA®/VAZKEPA® (icosapent ethyl) REDUCE-IT® Subgroup Data and New Mechanistic Insights into Eicosapentaenoic Acid...

Inhibitor Therapeutics, Inc. Provides Update on its Clinical Development Plan

By Global News Feed

TAMPA, Fla., Aug. 22, 2024 (GLOBE NEWSWIRE) -- Inhibitor Therapeutics, Inc. ("Inhibitor") (OTCQB: INTI) today provided an update on development efforts for its itraconazole formulation for the treatment of Basal Cell Carcinomas in patients with Basal Cell Carcinoma Nevus Syndrome, otherwise known as Gorlin Syndrome. Inhibitor has allied with The Gorlin Syndrome Alliance and sought supportive guidance from the accomplished and highly-experienced members of its Scientific Advisory Board in efforts to pursue an expeditious path to acceptance by the U.S. Food and Drug Administration (FDA).

More:
Inhibitor Therapeutics, Inc. Provides Update on its Clinical Development Plan

Firefly Neuroscience, an AI-Driven Brain Health Company, to Host Shareholder Update Call on September 4th

By Global News Feed

TORONTO, Aug. 22, 2024 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. (“Firefly,” “we,” or the “Company”) (NASDAQ: AIFF), an Artificial Intelligence (“AI”) technology company developing innovative neuroscientific solutions that improve brain health outcomes for patients with mental illnesses and neurological disorders, today announced management will host a shareholder update call on Wednesday, September 4, 2024 at 5:00 PM Eastern Time.

The rest is here:
Firefly Neuroscience, an AI-Driven Brain Health Company, to Host Shareholder Update Call on September 4th

Tevogen Bio Secures $6 Million Series C Preferred Stock Investment

By Global News Feed

WARREN, N.J., Aug. 22, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio Holdings Inc. (“Tevogen” or “Tevogen Bio”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech pioneer developing off-the-shelf, genetically unmodified T cell therapeutics in oncology, neurology, and virology, has entered into a definitive agreement for a $6.0 million Series C Preferred Stock investment with The Patel Family, LLP.

View original post here:
Tevogen Bio Secures $6 Million Series C Preferred Stock Investment

PharmAla Launches MDMA Clinical Trial Tool for Researchers

By Global News Feed

TORONTO, Aug. 22, 2024 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC:MDXXF), a biotechnology company focused on the research, development, and manufacturing of LaNeo™ MDMA and novel derivatives of MDMA (MDXX class molecules), is pleased to announce that it has created a new tool for researchers, providing direct access to its Chemistry, Manufacturing and Control (CMC) data – as well as its investigator’s brochure – to qualified researchers.

Visit link:
PharmAla Launches MDMA Clinical Trial Tool for Researchers

Pfizer and BioNTech Receive U.S. FDA Approval & Authorization for Omicron KP.2-adapted COVID-19 Vaccine

By Global News Feed

NEW YORK and MAINZ, GERMANY, August 22, 2024 — Pfizer Inc. (NYSE: PFE, “Pfizer”) and BioNTech SE (Nasdaq: BNTX, “BioNTech”) today announced that the U.S. Food and Drug Administration (“FDA”) has approved the supplemental Biologics License Application for individuals 12 years of age and older (COMIRNATY® (COVID-19 Vaccine, mRNA)), and granted emergency use authorization for individuals 6 months through 11 years of age (Pfizer-BioNTech COVID-19 Vaccine) of the companies’ Omicron KP.2-adapted 2024-2025 Formula COVID-19 vaccine. This season’s vaccine is for use as a single dose for most individuals 5 years of age and older. Individuals 5 years of age and older with certain kinds of immunocompromise previously vaccinated with Pfizer and BioNTech COVID-19 vaccines or children under the age of 5 who have not already completed a three-dose series with previous formulas of a COVID-19 vaccine may be eligible to receive additional doses.

Read the original post:
Pfizer and BioNTech Receive U.S. FDA Approval & Authorization for Omicron KP.2-adapted COVID-19 Vaccine

Adaptive Biotechnologies to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference

By Global News Feed

SEATTLE, Aug. 22, 2024 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will be participating in the upcoming Morgan Stanley 22nd Annual Global Healthcare Conference in New York, NY.

Read more here:
Adaptive Biotechnologies to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference

Seer to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference

By Global News Feed

REDWOOD CITY, Calif., Aug. 22, 2024 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today announced that the company will be participating in the upcoming Morgan Stanley 22nd Annual Global Healthcare Conference in New York, NY.

Go here to see the original:
Seer to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference

Travere Therapeutics to Present Abstracts at the Society for the Study of Inborn Errors of Metabolism Annual Symposium 2024

By Global News Feed

Posters to be presented highlight clinical study designs investigating pegtibatinase as the first potential disease-modifying treatment for classical homocystinuria Posters to be presented highlight clinical study designs investigating pegtibatinase as the first potential disease-modifying treatment for classical homocystinuria

Link:
Travere Therapeutics to Present Abstracts at the Society for the Study of Inborn Errors of Metabolism Annual Symposium 2024

Eton Pharmaceuticals to Participate at the H.C. Wainwright 26th Annual Global Investment Conference

By Global News Feed

DEER PARK, Ill., Aug. 22, 2024 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, announced today that the Company will participate at the H.C. Wainwright 26th Annual Global Investment Conference in New York City.

Read the rest here:
Eton Pharmaceuticals to Participate at the H.C. Wainwright 26th Annual Global Investment Conference

→←